TREATMENT OF ESTABLISHED RENAL-CANCER BY TUMOR-CELLS ENGINEERED TO SECRETE INTERLEUKIN-4

被引:769
|
作者
GOLUMBEK, PT
LAZENBY, AJ
LEVITSKY, HI
JAFFEE, LM
KARASUYAMA, H
BAKER, M
PARDOLL, DM
机构
[1] JOHNS HOPKINS UNIV, DEPT MED, BALTIMORE, MD 21205 USA
[2] JOHNS HOPKINS UNIV, DEPT PATHOL, BALTIMORE, MD 21205 USA
[3] JOHNS HOPKINS UNIV, DEPT IMMUNOL, BALTIMORE, MD 21205 USA
关键词
D O I
10.1126/science.1948050
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.
引用
收藏
页码:713 / 716
页数:4
相关论文
共 50 条
  • [31] Internalization property of interleukin-4 receptor a chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells
    Kawakami, K
    Kawakami, M
    Leland, P
    Puri, RK
    CLINICAL CANCER RESEARCH, 2002, 8 (01) : 258 - 266
  • [32] Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: a potentiality for cancer gene therapy
    Kimura, M
    Tagawa, M
    Takenaga, K
    Kondo, F
    Yamaguchi, T
    Saisho, H
    Nakagawara, A
    Sakiyama, S
    CANCER LETTERS, 1998, 128 (01) : 47 - 53
  • [33] Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells
    Turgeon, C
    Gingras, S
    Carrière, MC
    Blais, Y
    Labrie, F
    Simard, J
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1998, 65 (1-6): : 151 - 162
  • [34] Nasal polyps are characterized by a population of CD109+CRTH2-Th2 cells that secrete interleukin-4 and interleukin-10
    Ma, Junjie
    Tibbitt, Christopher Andrew
    Georen, Susanna Kumlien
    Georen, Susanna Kumlien
    Christian, Murray
    Murrell, Ben
    Cardell, Lars Olaf
    Cardell, Lars Olaf
    Bachert, Claus
    Bachert, Claus
    Bachert, Claus
    Coquet, Jonathan Mario
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 260 - 260
  • [35] Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells
    Chi, Lianhua
    Na, Moon-Hee
    Jung, Hyun-Kyung
    Vadevoo, Sri Murugan Poongkavithai
    Kim, Cheong-Wun
    Padmanaban, Guruprasath
    Park, Tae-In
    Park, Jae-Yong
    Hwang, Ilseon
    Park, Keon Uk
    Liang, Frank
    Lu, Maggie
    Park, Jiho
    Kim, In-San
    Lee, Byung-Heon
    JOURNAL OF CONTROLLED RELEASE, 2015, 209 : 327 - 336
  • [36] Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13
    Bessis, N
    Boissier, MC
    Ferrara, P
    Blankenstein, T
    Fradelizi, D
    Fournier, C
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (10) : 2399 - 2403
  • [37] TREATMENT OF ESTABLISHED LONG METASTASES WITH TUMOR-INFILTRATING LYMPHOCYTES DERIVED FROM A POORLY IMMUNOGENIC TUMOR ENGINEERED TO SECRETE HUMAN TNF-ALPHA
    MARINCOLA, FM
    ETTINGHAUSEN, S
    COHEN, PA
    CHESHIRE, LB
    RESTIFO, NP
    MULE, JJ
    ROSENBERG, SA
    JOURNAL OF IMMUNOLOGY, 1994, 152 (07): : 3501 - 3513
  • [38] ADJUVANT TREATMENT OF LOCALLY ADVANCED RENAL-CANCER WITH AUTOLOGOUS VIRUS-MODIFIED TUMOR VACCINES
    KIRCHNER, HH
    ANTON, P
    ATZPODIEN, J
    WORLD JOURNAL OF UROLOGY, 1995, 13 (03) : 171 - 173
  • [39] EFFICACY OF TNF-ALPHA GENE-TRANSDUCED TUMOR-CELLS IN TREATMENT OF ESTABLISHED IN-VIVO TUMOR
    KOSHITA, Y
    LU, Y
    FUJII, S
    NEDA, H
    MATSUYAMA, T
    SATOH, Y
    ITOH, Y
    TAKAHASHI, M
    KATO, J
    SAKAMAKI, S
    WATANABE, N
    KOHGO, Y
    NIITSU, Y
    INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (01) : 130 - 135
  • [40] Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4
    Saimura, M
    Nagai, E
    Mizumoto, K
    Maehara, N
    Minamishima, YA
    Katano, M
    Matsumoto, K
    Nakamura, T
    Tanaka, M
    CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3243 - 3249